The role of polyamines in human cancer: prospects for drug combination therapies. Bachmann, Andre S 2016-10-25T22:44:55Z 2016-10-25T22:44:55Z 2004-12
dc.description.abstract Ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) are two key enzymes in polyamine (PA) biosynthesis and their inhibition leads to PA pool depletion and cell growth arrest. DFMO and SAM486A are specific inhibitors of ODC and AdoMetDC, respectively, and are the only two PA inhibitors, which have been clinically evaluated in Phase II and III cancer trials. However, drug combination therapies expected to potentiate the effects of these drugs have yet to be systematically pursued. Human cancer trials (e.g. for the treatment of neuroblastoma patients) using a DFMO/SAM486A cocktail, possibly combined with current cytotoxic drugs and concomitant with a PA-deficient diet, are warranted.
dc.identifier.issn 0017-8594
dc.identifier.pubmed 15704548
dc.language.iso eng
dc.subject.mesh Amidines/administration & dosage
dc.subject.mesh Antineoplastic Combined Chemotherapy Protocols/therapeutic use
dc.subject.mesh Eflornithine/administration & dosage
dc.subject.mesh Humans
dc.subject.mesh Indans/administration & dosage
dc.subject.mesh Neoplasms/drug therapy/etiology
dc.subject.mesh Polyamines/antagonists & inhibitors/metabolism
dc.title The role of polyamines in human cancer: prospects for drug combination therapies.
dc.type Article
dc.type.dcmi Text
prism.number 12
prism.pagerange 371-4
prism.publicationname Hawaii Medical Journal
prism.volume 63
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
471.34 KB
Adobe Portable Document Format